NCT07072221View on ClinicalTrials.gov

Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

August 1, 2029

Study Completion Date

November 1, 2029

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

BCL regimen

"Induction therapy period (28 days\*6)~Bendamustine; Specification: 100mg per vial; 90mg/m2 d1-2, ivgtt.; for age≤70 years; 70mg/m2 d1-2, ivgtt.; for age\>70 years;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks, po.; for age≤70 years; 15mg biw for 2 weeks, po.; for age\>70 years;~Lenalidomide Specification:10mg per tablet; 10mg qd d1-d21, po.; for age≤70 years; 10mg qd d1-d14, po.; for age\>70 years;"

PROCEDURE

Cohort 1 (ASCT-eligible)

"Autologous hematopoietic stem cell transplantation~SEAM conditioning~Simustine 250mg/m2 orally, d1;~Etoposide 200mg/m2 intravenous infusion, d2-d5;~Cytarabine 400mg/m2 intravenous infusion, d2-d5;~Metformin 140mg/m2 intravenous infusion, d6;"

DRUG

Cohort 2 (ASCT--ineligible)

"Maintenance therapy period (2 years)~Chidamide; Specification: 5mg per tablet; 15mg biw for 2 weeks per 3 weeks, po.;"

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER